Qualitative evaluation of adherence therapy in Parkinson’s disease: a multidirectional model

Figures & data

Figure 1 Adherence therapy components and skills.

Table 1 Baseline characteristics of interview participants

Participant	Age, years	Sex	H&Y	Duration of PD (years)	MoCA	HADS		LEDD (mg)	PD drugs	Daily doses
						Anxiety	Depression
1	56	Male	3	7	25	6	11	640	1	4
2	69	Male	2	7	28	6	3	740	2	7
3	72	Female	1	2	18	10	6	1,038	2	4
4	63	Male	3	4	27	5	2	1,758	4	12
5	71	Female	3	14	26	4	5	2,319	5	18
6	68	Female	1	6	30	4	3	247.5	2	4
7	72	Female	4	14	25	9	7	900	3	9
8	87	Female	0	2	24	3	1	187.5	1	3
9	80	Female	3	2	28	8	7	312.5	2	5
10	53	Female	1	8	27	13	10	480	3	13

Abbreviations: H&Y, Hoehn and Yahr; MoCA, Montreal Cognitive Assessment Scale; HADS, Hospital Anxiety and Depression Scale; LEDD, levodopa equivalent daily doses; PD, Parkinson’s disease.

Table 2 Themes generated by thematic analysis

Theme	Subtheme	PD patients (n)
Perceptions prior to adherence therapy	Poor knowledge and understanding of PD and medications	9
	Low mood/confidence	5
	Decreased support/isolation	5
Positive effects of adherence therapy	Increased acceptance	5
	Increased self-awareness	5
	Increased confidence	4
	Increased knowledge/understanding of PD/medications	10
	Increased control/self-discipline	6
	Improved relationships	4
Attributes of adherence therapy	Therapy attributes
	Flexibility, continuity, and timing	6
	Involved spouse	3
	Face-to-face in home environment	10
	Time to talk/openness	8
	Therapist attributes
	Specialist knowledge	10
	Understanding and interest	6
	Equal relationship	7
	Easy to understand	5

Abbreviation: PD, Parkinson’s disease.

Figure 2 Multidirectional model of adherence therapy in Parkinson’s disease.

Abbreviation: PD, Parkinson’s disease.

Figure S1 Interview question prompts.